Works matching AU Bartlett, Nancy

Results: 128
    1
    2
    3

    Mosunetuzumab Monotherapy Demonstrates Durable Efficacy and Manageable Safety in Patients With Relapsed/Refractory Follicular Lymphoma and =2 Prior Therapies: Updated Results From a Pivotal Phase 2 Study.

    Published in:
    Journal of Oncology Navigation & Survivorship, 2023, v. 14, n. 11, p. 359
    By:
    • Bartlett, Nancy L.;
    • Sehn, Laurie H.;
    • Matasar, Matthew;
    • Schuster, Stephen J.;
    • Assouline, Sarit;
    • Giri, Pratyush;
    • Kuruvilla, John;
    • Canales, Miguel;
    • Dietrich, Sascha;
    • Fay, Keith;
    • Ku, Matthew;
    • Nastoupil, Loretta;
    • Wei, Michael C.
    Publication type:
    Article
    4

    Interdisciplinary Management of Chemorefractory NHL Patients Treated with KTE-C19 (Anti-CD19 CAR T Cells) in Phase 1 of the ZUMA-1 Clinical Study.

    Published in:
    Journal of Oncology Navigation & Survivorship, 2016, v. 7, n. 9, p. 56
    By:
    • Beaupierre, Alix;
    • Patterson, Amy;
    • Kahle, Nicole;
    • Locke, Frederick L.;
    • Neelapu, Sattva S.;
    • Bartlett, Nancy L.;
    • Siddiqi, Tanya;
    • Chavez, Julio C.;
    • Hosing, Chitra M.;
    • Cashen, Amanda;
    • Budde, Lihua E.;
    • Navale, Lynn;
    • Yizhou Jiang;
    • Elias, Meg;
    • Aycock, Jeff;
    • Wiezorek, Jeff;
    • Go, William Y.
    Publication type:
    Article
    5

    Metabolic Biomarkers Assessed with PET/CT Predict Sex-Specific Longitudinal Outcomes in Patients with Diffuse Large B-Cell Lymphoma.

    Published in:
    Cancers, 2022, v. 14, n. 12, p. 2932, doi. 10.3390/cancers14122932
    By:
    • Jaswal, Shama;
    • Sanders, Vanessa;
    • Pullarkat, Priyanka;
    • Teja, Stephanie;
    • Salter, Amber;
    • Watkins, Marcus P.;
    • Atagu, Norman;
    • Ludwig, Daniel R.;
    • Mhlanga, Joyce;
    • Mellnick, Vincent M.;
    • Peterson, Linda R.;
    • Bartlett, Nancy L.;
    • Kahl, Brad S.;
    • Fehniger, Todd A.;
    • Ghobadi, Armin;
    • Cashen, Amanda F.;
    • Mehta-Shah, Neha;
    • Ippolito, Joseph E.
    Publication type:
    Article
    6
    7

    Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study.

    Published in:
    Journal of Hematology & Oncology, 2023, v. 16, n. 1, p. 1, doi. 10.1186/s13045-023-01448-y
    By:
    • Epperla, Narendranath;
    • Welkie, Rina Li;
    • Torka, Pallawi;
    • Shouse, Geoffrey;
    • Karmali, Reem;
    • Shea, Lauren;
    • Anampa-Guzmán, Andrea;
    • Oh, Timothy S.;
    • Reaves, Heather;
    • Tavakkoli, Montreh;
    • Lindsey, Kathryn;
    • Greenwell, Irl Brian;
    • Hansinger, Emily;
    • Thomas, Colin;
    • Chowdhury, Sayan Mullick;
    • Annunzio, Kaitlin;
    • Christian, Beth;
    • Barta, Stefan K.;
    • Geethakumari, Praveen Ramakrishnan;
    • Bartlett, Nancy L.
    Publication type:
    Article
    8
    9
    10
    11

    Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study.

    Published in:
    Leukemia & Lymphoma, 2023, v. 64, n. 1, p. 130, doi. 10.1080/10428194.2022.2136956
    By:
    • Kuruvilla, John;
    • Armand, Philippe;
    • Hamadani, Mehdi;
    • Kline, Justin;
    • Moskowitz, Craig H.;
    • Avigan, David;
    • Brody, Joshua D.;
    • Ribrag, Vincent;
    • Herrera, Alex F.;
    • Morschhauser, Franck;
    • Kanate, Abraham;
    • Zinzani, Pier Luigi;
    • Bitran, Jacob;
    • Ghesquieres, Herve;
    • Schuster, Stephen J.;
    • Farooqui, Mohammed;
    • Marinello, Patricia;
    • Bartlett, Nancy L.
    Publication type:
    Article
    12
    13

    Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma.

    Published in:
    Leukemia & Lymphoma, 2022, v. 63, n. 4, p. 821, doi. 10.1080/10428194.2021.2010057
    By:
    • Halwani, Ahmad S.;
    • Panizo, Carlos;
    • Isufi, Iris;
    • Herrera, Alex F.;
    • Okada, Craig Y.;
    • Cull, Elizabeth H.;
    • Kis, Bela;
    • Chaves, Jorge M.;
    • Bartlett, Nancy L.;
    • Ai, Weiyun;
    • de la Cruz-Merino, Luis;
    • Bryan, Locke J.;
    • Houot, Roch;
    • Linton, Kim;
    • Briones, Javier;
    • Chau, Ian;
    • von Keudell, Gottfried R.;
    • Lu, Hailing;
    • Yakovich, Adam;
    • Chen, Michael
    Publication type:
    Article
    14
    15
    16

    Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

    Published in:
    Leukemia & Lymphoma, 2020, v. 61, n. 13, p. 3188, doi. 10.1080/10428194.2020.1795159
    By:
    • Fraser, Graeme A.M.;
    • Chanan-Khan, Asher;
    • Demirkan, Fatih;
    • Santucci Silva, Rodrigo;
    • Grosicki, Sebastian;
    • Janssens, Ann;
    • Mayer, Jiri;
    • Bartlett, Nancy L.;
    • Dilhuydy, Marie-Sarah;
    • Loscertales, Javier;
    • Avigdor, Abraham;
    • Rule, Simon;
    • Samoilova, Olga;
    • Pavlovsky, Miguel A.;
    • Goy, Andre;
    • Mato, Anthony;
    • Hallek, Michael;
    • Salman, Mariya;
    • Tamegnon, Monelle;
    • Sun, Steven
    Publication type:
    Article
    17
    18
    19
    20

    Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry.

    Published in:
    Leukemia & Lymphoma, 2017, v. 58, n. 7, p. 1607, doi. 10.1080/10428194.2016.1256481
    By:
    • Bartlett, Nancy L.;
    • Smith, Mitchell R.;
    • Siddiqi, Tanya;
    • Advani, Ranjana H.;
    • O'Connor, Owen A.;
    • Sharman, Jeff P.;
    • Feldman, Tatyana;
    • Savage, Kerry J.;
    • Shustov, Andrei R.;
    • Diefenbach, Catherine S.;
    • Oki, Yasuhiro;
    • Palanca-Wessels, Maria Corinna;
    • Uttarwar, Mayur;
    • Li, Martha;
    • Yang, Jing;
    • Jacobsen, Eric D.
    Publication type:
    Article
    21
    22
    23

    Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial

    Published in:
    Leukemia & Lymphoma, 2015, v. 56, n. 9, p. 2569, doi. 10.3109/10428194.2015.1007504
    By:
    • Fayad, Luis;
    • Ansell, Stephen M.;
    • Advani, Ranjana;
    • Coiffier, Bertrand;
    • Stuart, Robert;
    • Bartlett, Nancy L.;
    • Forero-Torres, Andres;
    • Kuliczkowski, Kazimierz;
    • Belada, David;
    • Ng, Edmund;
    • Drachman, Jonathan G.
    Publication type:
    Article
    24
    25
    26
    27
    28
    29
    30

    Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403.

    Published in:
    American Journal of Hematology, 2020, v. 95, n. 6, p. 583, doi. 10.1002/ajh.25783
    By:
    • Kaplan, Lawrence D.;
    • Maurer, Matthew J.;
    • Stock, Wendy;
    • Bartlett, Nancy L.;
    • Fulton, Noreen;
    • Pettinger, Adam;
    • Byrd, John C.;
    • Blum, Kristie A.;
    • LaCasce, Ann S.;
    • Hsi, Eric D.;
    • Liu, Yi Tian;
    • Scott, David W.;
    • Hurd, David;
    • Ruppert, Amy S.;
    • Hernandez‐Ilizaliturri, Francisco;
    • Leonard, John P.;
    • Cheson, Bruce D.
    Publication type:
    Article
    31

    Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration.

    Published in:
    American Journal of Hematology, 2016, v. 91, n. 9, p. 894, doi. 10.1002/ajh.24429
    By:
    • Cheah, Chan Y.;
    • Bröckelmann, Paul J.;
    • Chihara, Dai;
    • Moskowitz, Alison J.;
    • Engert, Andreas;
    • Jerkeman, Mats;
    • El-Galaly, Tarec C.;
    • Augustson, Bradley;
    • Vose, Julie;
    • Bartlett, Nancy L.;
    • Villa, Diego;
    • Connors, Joseph M.;
    • Feldman, Tatyana;
    • Pinnix, Chelsea C.;
    • Milgrom, Sarah A.;
    • Dabaja, Bouthaina;
    • Oki, Yasuhiro;
    • Fanale, Michelle A.
    Publication type:
    Article
    32

    Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: Characteristics, outcomes, and prognostication among a large multicenter cohort.

    Published in:
    American Journal of Hematology, 2015, v. 90, n. 9, p. 778, doi. 10.1002/ajh.24082
    By:
    • Evens, Andrew M.;
    • Kanakry, Jennifer A.;
    • Sehn, Laurie H.;
    • Kritharis, Athena;
    • Feldman, Tatyana;
    • Kroll, Aimee;
    • Gascoyne, Randy D.;
    • Abramson, Jeremy S.;
    • Petrich, Adam M.;
    • Hernandez-Ilizaliturri, Francisco J.;
    • Al-Mansour, Zeina;
    • Adeimy, Camille;
    • Hemminger, Jessica;
    • Bartlett, Nancy L.;
    • Mato, Anthony;
    • Caimi, Paolo F.;
    • Advani, Ranjana H.;
    • Klein, Andreas K.;
    • Nabhan, Chadi;
    • Smith, Sonali M.
    Publication type:
    Article
    33

    Evaluation of Ki-67 expression and large cell content as prognostic markers in MZL: a multicenter cohort study.

    Published in:
    Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01162-z
    By:
    • Grover, Natalie S.;
    • Annunzio, Kaitlin;
    • Watkins, Marcus;
    • Torka, Pallawi;
    • Karmali, Reem;
    • Anampa-Guzmán, Andrea;
    • Oh, Timothy S.;
    • Reves, Heather;
    • Tavakkoli, Montreh;
    • Hansinger, Emily;
    • Christian, Beth;
    • Thomas, Colin;
    • Barta, Stefan K.;
    • Geethakumari, Praveen Ramakrishnan;
    • Bartlett, Nancy L.;
    • Shouse, Geoffrey;
    • Olszewski, Adam J.;
    • Epperla, Narendranath
    Publication type:
    Article
    34
    35
    36

    Bendamustine/Rituximab Plus Cytarabine/Rituximab, With or Without Acalabrutinib, for the Initial Treatment of Transplant-Eligible Mantle Cell Lymphoma Patients: Pooled Data From Two Pilot Studies.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 7, p. 552, doi. 10.1016/j.clml.2023.04.003
    By:
    • Patel, Dilan A.;
    • Wan, Fei;
    • Trinkaus, Kathryn;
    • Guy, Daniel G.;
    • Edwin, Natasha;
    • Watkins, Marcus;
    • Bartlett, Nancy L.;
    • Cashen, Amanda;
    • Fehniger, Todd A.;
    • Ghobadi, Armin;
    • Shah, Neha-Mehta;
    • Kahl, Brad S.
    Publication type:
    Article
    37

    Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. e435, doi. 10.1016/j.clml.2021.12.012
    By:
    • Hamid, Muhammad Saad;
    • Rutherford, Sarah C.;
    • Jang, Hyejeong;
    • Kim, Seongho;
    • Patel, Krish;
    • Bartlett, Nancy L.;
    • Malecek, Mary-Kate;
    • Watkins, Marcus P.;
    • Maddocks, Kami J.;
    • Bond, David A.;
    • Feldman, Tatyana A.;
    • Magarelli, Gabriela;
    • Advani, Ranjana H;
    • Spinner, Michael A;
    • Evens, Andrew M.;
    • Shah, Mansi;
    • Ahmed, Sairah;
    • Stephens, Deborah M.;
    • Allen, Pamela;
    • Tees, Michael T.
    Publication type:
    Article
    38

    Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional Experience.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 5, p. e300, doi. 10.1016/j.clml.2021.10.018
    By:
    • Bennani, N. Nora;
    • Tun, Aung M.;
    • Carson, Kenneth R;
    • Geiger, Jessica L;
    • Maeda, Lauren S;
    • Savage, Kerry J;
    • Rose, Jim;
    • Pinter-Brown, Lauren;
    • Lunning, Matthew A;
    • Abramson, Jeremy S;
    • Bartlett, Nancy L;
    • Vose, Julie M;
    • Evens, Andrew M;
    • Smith, Sonali M;
    • Horwitz, Steven M;
    • Ansell, Stephen M.;
    • Advani, Ranjana H
    Publication type:
    Article
    39

    Characteristics and Outcome of Extranodal NK/T-Cell Lymphoma in North America: A Retrospective Multi-Institutional Experience.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 4, p. e250, doi. 10.1016/j.clml.2021.10.004
    By:
    • Bennani, N. Nora;
    • Tun, Aung M.;
    • Carson, Kenneth R.;
    • Geiger, Jessica L.;
    • Maeda, Lauren S.;
    • Savage, Kerry J.;
    • Rose, Jim;
    • Pinter-Brown, Lauren;
    • Lunning, Matthew A.;
    • Abramson, Jeremy S.;
    • Bartlett, Nancy L.;
    • Vose, Julie M.;
    • Evens, Andrew M.;
    • Smith, Sonali M.;
    • Horwitz, Steven M.;
    • Ansell, Stephen M.;
    • Advani, Ranjana H.
    Publication type:
    Article
    40

    TCL-150: The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S411, doi. 10.1016/S2152-2650(21)01925-X
    By:
    • Iyer, Swaminathan;
    • Trümper, Lorenz;
    • O'Connor, Owen A.;
    • Pro, Barbara;
    • Illidge, Tim;
    • Advani, Ranjana;
    • Bartlett, Nancy L.;
    • Christensen, Jacob Haaber;
    • Morschhauser, Franck;
    • Domingo-Domenech, Eva;
    • Rossi, Giuseppe;
    • Won Seog Kim;
    • Feldman, Tatyana;
    • Menne, Tobias;
    • Belada, David;
    • Illès, Árpád;
    • Tobinai, Kensei;
    • Kunihiro Tsukasaki;
    • Su-Peng Yeh;
    • Shustov, Andrei
    Publication type:
    Article
    41

    IBCL-373: Updated Experience from Mosunetuzumab in Multiple Relapsed Follicular Lymphoma: Promising Efficacy from a Phase I Trial.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S406, doi. 10.1016/S2152-2650(21)01916-9
    By:
    • Assouline, Sarit;
    • Won Seog Kim;
    • Sehn, Laurie H.;
    • Schuster, Stephen J.;
    • Chan Yoon Cheah;
    • Nastoupil, Loretta J.;
    • Shadman, Mazyar;
    • Sung-Soo Yoon;
    • Matasar, Matthew J.;
    • Diefenbach, Catherine;
    • Gregory, Gareth P.;
    • Bartlett, Nancy L.;
    • Wei, Michael C.;
    • Doral, Michelle Y.;
    • Shen Yin;
    • Negricea, Raluca;
    • Chi-Chung Li;
    • Penuel, Elicia;
    • Huang Huang;
    • Budde, L. Elizabeth
    Publication type:
    Article
    42

    HL-147: Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S371, doi. 10.1016/S2152-2650(21)01849-8
    By:
    • Ramchandren, Radhakrishnan;
    • Dfugosz-Danecka, Monika;
    • Connors, Joseph M.;
    • Radford, John;
    • Illés, Árpád;
    • Picardi, Marco;
    • Lech-Maranda, Ewa;
    • Feldman, Tatyana;
    • Smolewski, Piotr;
    • Savage, Kerry J.;
    • Bartlett, Nancy L.;
    • Walewski, Jan;
    • Zinzani, Pier Luigi;
    • Hutchings, Martin;
    • Munoz, Javier;
    • Won Seog Kim;
    • Advani, Ranjana;
    • Ansell, Stephen M.;
    • Gallamini, Andrea;
    • Alekseev, Sergey
    Publication type:
    Article
    43

    Poster: TCL-150: The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S247, doi. 10.1016/S2152-2650(21)01557-3
    By:
    • Iyer, Swaminathan;
    • Trümper, Lorenz;
    • O'Connor, Owen A.;
    • Pro, Barbara;
    • Illidge, Tim;
    • Advani, Ranjana;
    • Bartlett, Nancy L.;
    • Christensen, Jacob Haaber;
    • Morschhauser, Franck;
    • Domingo-Domenech, Eva;
    • Rossi, Giuseppe;
    • Kim, Won Seog;
    • Feldman, Tatyana;
    • Menne, Tobias;
    • Belada, David;
    • Illès, Árpád;
    • Tobinai, Kensei;
    • Tsukasaki, Kunihiro;
    • Yeh, Su-Peng;
    • Shustov, Andrei
    Publication type:
    Article
    44

    Poster: IBCL-373: Updated Experience from Mosunetuzumab in Multiple Relapsed Follicular Lymphoma: Promising Efficacy from a Phase I Trial.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S245, doi. 10.1016/S2152-2650(21)01540-8
    By:
    • Assouline, Sarit;
    • Kim, Won Seog;
    • Sehn, Laurie H.;
    • Schuster, Stephen J.;
    • Cheah, Chan Yoon;
    • Nastoupil, Loretta J.;
    • Shadman, Mazyar;
    • Yoon, Sung-Soo;
    • Matasar, Matthew J.;
    • Diefenbach, Catherine;
    • Gregory, Gareth P.;
    • Bartlett, Nancy L.;
    • Wei, Michael C.;
    • Doral, Michelle Y.;
    • Yin, Shen;
    • Negricea, Raluca;
    • Li, Chi-Chung;
    • Penuel, Elicia;
    • Huang, Huang;
    • Budde, L. Elizabeth
    Publication type:
    Article
    45

    Poster: HL-147: Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S236, doi. 10.1016/S2152-2650(21)01485-3
    By:
    • Ramchandren, Radhakrishnan;
    • Długosz-Danecka, Monika;
    • Connors, Joseph M.;
    • Radford, John;
    • Illés, Árpád;
    • Picardi, Marco;
    • Lech-Maranda, Ewa;
    • Feldman, Tatyana;
    • Smolewski, Piotr;
    • Savage, Kerry J.;
    • Bartlett, Nancy L.;
    • Walewski, Jan;
    • Zinzani, Pier Luigi;
    • Hutchings, Martin;
    • Munoz, Javier;
    • Won Seog Kim;
    • Advani, Ranjana;
    • Ansell, Stephen M.;
    • Gallamini, Andrea;
    • Alekseev, Sergey
    Publication type:
    Article
    46

    Oral Abstract: TCL-150: The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S203, doi. 10.1016/S2152-2650(21)01276-3
    By:
    • Iyer, Swaminathan;
    • Trümper, Lorenz;
    • O'Connor, Owen A.;
    • Pro, Barbara;
    • Illidge, Tim;
    • Advani, Ranjana;
    • Bartlett, Nancy L.;
    • Christensen, Jacob Haaber;
    • Morschhauser, Franck;
    • Domingo-Domenech, Eva;
    • Rossi, Giuseppe;
    • Won Seog Kim;
    • Feldman, Tatyana;
    • Menne, Tobias;
    • Belada, David;
    • Illès, Árpád;
    • Tobinai, Kensei;
    • Tsukasaki, Kunihiro;
    • Su-Peng Yeh;
    • Shustov, Andrei
    Publication type:
    Article
    47
    48

    Managing Cytokine Release Syndrome and Neurotoxicity with Step-Up Dosing of Mosunetuzumab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S247, doi. 10.1016/j.clml.2019.07.151
    By:
    • Bartlett, Nancy L.;
    • Sehn, Laurie H.;
    • Assouline, Sarit;
    • Bosch, Francesc;
    • Diefenbach, Catherine M.;
    • Flinn, Ian;
    • Hong, Jung Yong;
    • Kim, Wonseog S.;
    • Matasar, Matthew;
    • Nastoupil, Loretta;
    • Schuster, Stephen J.;
    • Shadman, Mazyar;
    • Yoon, Sung-Soo;
    • Bender, Brendan;
    • Chu, Wayne;
    • Hernandez, Genevive;
    • Kwan, Antonia;
    • McCall, Bruce;
    • Sison, Iris;
    • Wang, Cunlin
    Publication type:
    Article
    49
    50